Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: A 12-week, randomized, double-blind study

Journal of Drugs in Dermatology

Volumn 9, Issue 1, 2010, Pages 33-40

  Fleischer Jr , Alan B ^a   Shalita, Alan ^b   Eichenfield, Lawrence F ^c,d   Abramovits, William ^e   Lucky, Anne ^f   Garrett, Steven ^g  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c RADY CHILDREN'S HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Dermatology Treatment and Research Center   (United States)

^f Dermatology Research Associates   (United States)

^g QLT USA Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; BENZOYL PEROXIDE; CETAPHIL; DAPSONE; UNCLASSIFIED DRUG; DERMATOLOGICAL AGENT; KERATOLYTIC AGENT; NAPHTHALENE DERIVATIVE;

ACNE VULGARIS; ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; ERYTHEMA; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SKIN ABRASION; TREATMENT DURATION; ADOLESCENT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; GEL; PATHOLOGY; TREATMENT OUTCOME;

ACNE VULGARIS; ADOLESCENT; ADULT; BENZOYL PEROXIDE; CHILD; DAPSONE; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; GELS; HUMANS; KERATOLYTIC AGENTS; MALE; NAPHTHALENES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77449116451     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Pawin H, Beylot C, Chivot M, et al. Physiopathology of acne vulgaris: recent data, new understanding of the treatments. Eur J Dermatol. 2004:14(1):4-12.
2. Harper JC, Thiboutot DM. Pathogenesis of acne: Recent research advances. Adv Dermatol. 2003;19:1-10.
3. Gollnick H, Cunliffe W, Berson D, et al; and Global Alliance to Improve Outcomes in Acne. Management of acne: A report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(1 Suppl):1S-37S.
4. Strauss JS, Krowchuk DP, Leyden JJ, et al; American Academy of Dermatology/American Academy of Dermatology Association. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007;56(4):651-663.
5. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003;49(3 Suppl):S200-S210.
6. Kazmierowski JA, Ross JE, Peizner DS, Wuepper KD. Dermatitis herpetiformis: Effects of sulfones and sulfonamides on neutrophil myeloperoxidase-mediated iodination and cytotoxicity. J Clin Immunol. 1984;4(1):55-64.
7. Maloff BL, Fox D, Bruin E, Di Meo TM. Dapsone inhibits LTB4 binding and bioresponse at the cellular and physiologic levels. Eur J Pharmacol. 1988;158(1-2):85-89.
8. Debol SM, Herron MJ, Nelson RD. Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukoc Biol. 1997;62(6):827-836.
9. Ross CM. The treatment of acne vulgaris with dapsone. Br J Dermatol. 1961;73:367 370.
10. Kaminsky CA, Kaminsky AR, Schicci C, Velazco de Morini M. Acne: Treatment with diaminodiphenylsulfone. Cutis. 1974;13:869-871.
11. Geniaux M, Meraud JP, Texier L. Experience with Disulone in the treatment of severe nodular acne [in French]. LARC Med. 1981;1:67.
12. Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: Overview and update. J Am Acad Dermatol. 2001;45(3):420-434.
13. Thiboutot DM, Willmer J, Sharata H, et al. Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris. Clin Pharmacokinet. 2007;46(8):697-712.
14. Draelos ZD, Carter E, Maloney JM, et al. for United States/Canada Dapsone Gel Study Group. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol. 2007;56(3):439.e1-439.e10.
15. Roberts J, Maloney M, Ling M, Lucky AW. Five percent dapsone topical gel: Safety and efficacy with long-term (one year) treatment for acne vulgaris. J Am Acad Dermatol. 2005;52:5.
16. Dosik JS, Homer K, Arsonnaud S. Cumulative irritation potential of adapalene 0.1% cream and gel compared to tazarotene cream 0.05% and 0.1%. Cutis. 2005;75(5):289-293.
17. Differin® Gel, 0.1% [package insert]. Fort Worth (TX): Galderma Laboratories, L.P.; 2003.